Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harmony Biosciences Holdings (HRMY) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Harmony Biosciences Holdings reported EPS of $0.81, below the $1.00 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 82.5% above the $0.57 reported for the quarter ended Dec 31, 2025.
HRMY's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
HRMY Earnings Call
The latest HRMY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, HRMY beat 16 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $268.92M, up 12.3% from $239.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.81 | $1.00 | N/A | -19.00% | Miss | -25.0% | 2 | 3 up, 0 down | Nov 4, 2026 | $268.92M |
| Jun 30, 2026 | $1.28 | $0.97 | N/A | +31.96% | Beat | +39.1% | 3 | 1 up, 1 down | Aug 4, 2026 | $261.28M |
| Mar 31, 2026 | $0.79 | $0.93 | $0.67 - $1.22 | -15.05% | Miss | +1.5% | 5 | 0 up, 2 down | May 7, 2026 | $215.39M |
| Dec 31, 2025 | $0.57 | $0.86 | N/A | -33.72% | Miss | -47.2% | 4 | 2 up, 0 down | Feb 24, 2026 | $243.78M |
| Sep 30, 2025 | $1.08 | $0.86 | $0.81 - $0.91 | +25.58% | Beat | +4.9% | 2 | 1 up, 0 down | Nov 4, 2025 | $239.46M |
| Jun 30, 2025 | $0.92 | $0.96 | $0.85 - $1.11 | -4.17% | Miss | -12.4% | 4 | 2 up, 1 down | Aug 5, 2025 | $200.49M |
| Mar 31, 2025 | $0.78 | $0.91 | $0.77 - $1.45 | -14.79% | Miss | -11.5% | 3 | 0 up, 1 down | May 6, 2025 | $184.73M |
| Dec 31, 2024 | $1.08 | $0.82 | $0.77 - $0.90 | +31.71% | Beat | +140.0% | 4 | 1 up, 0 down | Feb 25, 2025 | $201.27M |
| Sep 30, 2024 | $1.03 | $0.88 | N/A | +17.05% | Beat | +6.2% | 8 | 0 up, 1 down | Oct 29, 2024 | $186.04M |
| Jun 30, 2024 | $1.05 | $0.12 | N/A | +775.00% | Beat | +38.2% | 6 | 0 up, 2 down | Aug 6, 2024 | $172.81M |
| Mar 31, 2024 | $0.88 | $0.69 | N/A | +27.54% | Beat | +33.3% | 7 | 1 up, 1 down | Apr 30, 2024 | $154.62M |
| Dec 31, 2023 | $0.45 | $0.48 | $0.04 - $0.83 | -6.25% | Miss | -43.0% | 8 | 1 up, 1 down | Feb 22, 2024 | $168.41M |
| Sep 30, 2023 | $0.97 | $0.81 | N/A | +19.75% | Beat | +2.1% | 8 | 0 up, 1 down | Oct 31, 2023 | $160.27M |
| Jun 30, 2023 | $0.76 | $0.74 | N/A | +2.70% | Beat | +33.3% | 8 | 1 up, 1 down | Aug 1, 2023 | $134.22M |
| Mar 31, 2023 | $0.66 | $0.56 | $0.38 - $0.58 | +17.86% | Beat | +29.4% | 8 | 0 up, 0 down | May 2, 2023 | $119.13M |
| Dec 31, 2022 | $0.79 | $0.58 | $0.47 - $0.81 | +36.21% | Beat | +107.9% | 8 | 0 up, 0 down | Feb 21, 2023 | $128.31M |
| Sep 30, 2022 | $0.95 | $0.19 | -$0.04 - $0.44 | +400.00% | Beat | N/A | 7 | 0 up, 0 down | Nov 1, 2022 | $117.21M |
| Jun 30, 2022 | $0.57 | $0.63 | N/A | -9.52% | Miss | +137.5% | 7 | 0 up, 1 down | Aug 2, 2022 | $107.03M |
| Mar 31, 2022 | $0.51 | $0.42 | N/A | +21.43% | Beat | +34.2% | 7 | 2 up, 0 down | May 3, 2022 | $85.31M |
| Dec 31, 2021 | $0.38 | $0.36 | $0.27 - $0.47 | +5.56% | Beat | +52.0% | 6 | 1 up, 1 down | Feb 28, 2022 | $91.21M |
| Sep 30, 2021 | -$0.17 | $0.52 | N/A | -132.69% | Miss | N/A | 5 | N/A | Nov 9, 2021 | $80.73M |
| Jun 30, 2021 | $0.24 | $0.17 | $0.13 - $0.24 | +41.18% | Beat | N/A | 3 | N/A | Aug 10, 2021 | $73.82M |
| Mar 31, 2021 | $0.38 | -$0.01 | -$0.05 - -$0.01 | N/A | N/A | N/A | 3 | N/A | May 11, 2021 | $59.67M |
| Dec 31, 2020 | $0.25 | $0.09 | $0.05 - $0.16 | +177.78% | Beat | N/A | 3 | N/A | Mar 25, 2021 | $56.29M |
| Sep 30, 2020 | -$0.14 | -$0.15 | -$0.15 - $0.12 | +6.67% | Beat | N/A | 3 | N/A | Nov 12, 2020 | $45.61M |
| Jun 30, 2020 | -$2.93 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 19, 2020 | $38.01M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.35, down 17.1% from the year before. It was -$2.82 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.35 | -17.1% |
| Dec 31, 2024 | $4.04 | +42.3% |
| Dec 31, 2023 | $2.84 | N/A |
| Dec 31, 2022 | $2.82 | +239.8% |
| Dec 31, 2021 | $0.83 | N/A |
| Dec 31, 2020 | -$2.82 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,302 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,180 | 15 | |
| 2026Q1 | Mar 31, 2026 | 8,386 | 16 | |
| 2025Q4 | Dec 31, 2025 | 7,621 | 17 | |
| 2025Q3 | Sep 30, 2025 | 7,750 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,718 | 14 | |
| 2025Q1 | Mar 31, 2025 | 8,076 | 14 | |
| 2024Q4 | Dec 31, 2024 | 7,894 | 15 |
2026Q3 Earnings Call
Opening remarks
Brennan Doyle Head of Investor Relations Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' third quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany today's discussion. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Peter Anastasiou, Senior Executive Vice President, Chief Operating Officer, and incoming President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; and Steve Mollichella, Interim Principal Financial Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, Dr. Jeffrey Dayno. Jeff.
Jeffrey Dayno CEO Thank you, Brennan. Good morning, everyone, and thank you for joining our call today. Before I get into the quarter, I first want to say a few words about the CEO transition we announced last month. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer effective January 1st, 2027. I am confident that Harmony is in very good hands with Peter, and you will hear from him next. The main themes regarding the CEO transition are continuity, strength, and growth. This leadership transition does not signal any change in our overall business or our strategic priorities. We are doing this from a position of strength and executing a well-coordinated plan. Harmony continues to be a growth story, and during Q3, we moved that story forward in each of our four priorities of value creation: continue to grow WAKIX in an evolving market, advance a novel and robust clinical-stage pipeline, transact on strategic business development deals, and protect the pitolisant franchise. I will provide some more color on our first two strategic priorities of value creation and then turn it over to Peter to expand on our other two strategic priorities. The key highlights that I want you to take away from today's call are sustained patient demand-driven growth for WAKIX in its seventh year on the market, keeping us firmly on track to exceed $1 billion in net revenue this year, and preliminary multiple ascending dose data for our orexin-2 agonist, BP-205, that further strengthen its emerging best-in-class profile.
Frequently Asked Questions About HRMY
Did HRMY beat earnings estimates last quarter?
No. Harmony Biosciences Holdings reported EPS of $0.81 for the quarter ended Sep 30, 2026, below the $1.00 estimate by 19.00%.
What EPS do analysts expect from HRMY next quarter?
The consensus EPS estimate for Harmony Biosciences Holdings for the quarter ending Dec 31, 2026 is $1.04 from 14 analysts, with estimates from $0.60 to $1.61.
How often does HRMY beat earnings estimates?
Harmony Biosciences Holdings beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.31%.
HRMY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts